<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363811">
  <stage>Registered</stage>
  <submitdate>5/03/2013</submitdate>
  <approvaldate>7/03/2013</approvaldate>
  <actrnumber>ACTRN12613000274774</actrnumber>
  <trial_identification>
    <studytitle>The effects of minocycline on breathing during sleep in patients prescribed opioid drugs for chronic pain.</studytitle>
    <scientifictitle>A Phase IIa trial of patients on opioids for chronic pain, testing the efficacy of minocycline as a glial attenuator versus placebo on respiratory depression and analgesia.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Central sleep apnoea</healthcondition>
    <healthcondition>chronic pain</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Minocycline hydrochloride, 100 mg will be administered orally, twice daily for 3 days.

A washout period of at least 1 week will follow.

The study is randomised so the washout is between placebo then minocycline, or minocycline then placebo. the study is double-blinded, so only the statistician in this study will know.</interventions>
    <comparator>Placebo will be taken in the same frequency and duration as the intervention treatment. 

Minocycline will be "over-encapsulated" with a slightly larger capsule also used for placebos so they'll look identical and should taste (swallowed whole and probably minimal) the same</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>% of patients with central apnoea index &lt;5 /hr</outcome>
      <timepoint>3 days after starting administration of minocycline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>analgesia effectiveness scored by Brief Pain Inventory (BPI)</outcome>
      <timepoint>3 days after starting administration of minocycline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CO2 respiratory control sensitivity during wake, using pseudorandom binary stimulation test</outcome>
      <timepoint>3 days after starting administration of minocycline</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-	Age 18-65 years.
-	On prescribed oral long acting opioids within pre-specified dose ranges (morphine 40  500 mg /day, oxycodone 30  350mg/day or methadone 20  100 mg/day) .
-	Central sleep apnoea index greater or equal to 5 /hr.
Chronic pain patients will only be included if they are prescribed and taking the opioid medication mentioned above, so chronic pain by itself will not be an inclusion.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-	Clinically significant respiratory (e.g. COPD), cardiovascular (e.g. congestive cardiac failure, previous cerebro-vascular accident) or metabolic disorders.
-	Major psychiatric illness.
-	History of substance abuse.
-	Contra-indications to minocycline use, ie. Known allergies to tetracycline, severe renal insufficiency, systemic lupus erythematosus, pregnancy or breastfeeding, concurrent prescription and non-prescription medications, vitamins, nutritional supplements, or herbal products with known interactions with tetracylines (e.g. Vitamin A/retinoids).
-	Marked daytime sleepiness Epworth Sleepiness Scale (ESS) equal to or greater than 15.
-	Morbid obesity BMI equal to or greater than 35 kg/m2.
-	Concurrent central sleep apnoea treatment and unwilling or unable to come off treatment for in-laboratory study nights.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>12/03/2013</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>15</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <postcode>5041 - Daw Park</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Repatriation General Hospital</primarysponsorname>
    <primarysponsoraddress>Daws Road, Daw Park, SA, 5041, Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Repat Foundation</fundingname>
      <fundingaddress>Daws Road, Daw Park, SA, 5041, Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Australian Institute for Sleep Health</sponsorname>
      <sponsoraddress>Daws Road, Daw Park, SA,  5041, Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to find a new way of treating central sleep apnoea and drug tolerance caused by opioid medication prescribed for chronic pain. The medication tested in this study is Minocycline, a commonly used antibiotic with effects on the central nervous system's immune system.

Hypothesis
Minocycline will reduce the severity of central sleep apnoea in patients prescribed opioids for chronic pain.

Minocycline will increase the analgesic efficacy of opioids prescribed to chronic pain patients.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Flinders Dr  Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate>29/05/2013</ethicapprovaldate>
      <hrec>EC00188</hrec>
      <ethicsubmitdate>5/03/2013</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Peter Catcheside</name>
      <address>Adelaide Institute for Sleep Health
Daws Rd, Daw Park, 5041
South Australia</address>
      <phone>+64 (08) 8275 1309</phone>
      <fax />
      <email>peter.catcheside@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Michael Mogford</name>
      <address>Adelaide Institute for Sleep Health
Daws Rd, Daw Park, 5041
South Australia</address>
      <phone>+64 468 962 749</phone>
      <fax />
      <email>michael.mogford@student.adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Michael Mogford</name>
      <address>Adelaide Institute for Sleep Health
Daws Rd, Daw Park, 5041
South Australia</address>
      <phone>+64 468 962 749</phone>
      <fax />
      <email>michael.mogford@student.adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>